Blockade of Pin1 prevents cytokine production by activated...

Details Blockade of Pin1 prevents cytokine production by activated... Blockade of Pin1 prevents cytokine production by activated...

2006-05-12

2008-08-26

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ketone doai

C514S690000, C524S358000, C568S037000

Reexamination Certificate

active

07417072

ABSTRACT:
The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5984088 (1999-11-01), Dietz et al.
patent: 036676 (1981-09-01), None
patent: 058481 (1982-08-01), None
patent: 088046 (1983-09-01), None
patent: 133988 (1985-03-01), None
patent: 143949 (1985-06-01), None
patent: 1402888 (2004-03-01), None
patent: 93/00829 (1993-08-01), None
patent: 94/001875 (1994-09-01), None
patent: WO 88/01649 (1998-03-01), None
patent: WO 99/07409 (1999-02-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 00/01846 (2000-01-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/36646 (2001-05-01), None
Filipovic M, Cekic S, The Role of Eosinophils in Asthma, Medicine and Biology, 2001, 8(1): 6-10.
Asthma in the Merck Index.
Bai J, Peat JK, Berry G, Marks GB, Wookcock AJ, Questionnaire items that predict asthma and other repiratory conditions in adults, Chest, 1998, 114: 1343-1348.
Eosinphil count-absolute from the Medical Encyclopedia.
Joseph JD, Yeh ES, Wendson KI, Means AR, THe peptidyl-prolyl isomease Pin1, Progress in Cell Cycle Research, 2003, 5:477-457.
Ryo A, Liou Y-C, Lu KP, Wulf G, Journal of Cell Science, 2003, 116:773-783.
Eosinophilia in the Merck Index, Accessed Feb. 2, 2007.
About EGID in the Apfed, Accessed Feb. 5, 2007.
Maruyama T. Furutani M, Archaeal Peptidyl Prolyl Cis-trans Isomerase (PPlases), Frontiers in Bioscience 5, 2000, d821-836.
Asthma in the Merck Index, Accessed Feb. 2, 2007.
Eosinophil count-absolute from the Medical Encyclopedia, Accessed Feb. 7, 2007.
Bass, 2001, “RNA interference: The short answer”,Nature411:428-429.
Elbashir et al., 2001, “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”,Nature411:494-498.
Martinez et al., 2002, “Single-stranded antisense siRNAs guide target RNA cleavage in RNAi”,Cell110(5):563-74.
Schwarz et al., 2002, “Evidence that siRNAs function as guides, not primers, in the Drosophilia and human RNAi pathways.”,Molecular Cell10(3):537-48.
GenBank Accession No. NM—006221 (GenBank, NCBI).
Thompson and Ellman, 1996, “Synthesis and Applications of Small Molecule Libraries”,Chem. Rev.96(1):555-600.
Goodford, 1985, “A computational procedure for determining energetically favorable binding sites on biologically important macromolecules”,J. Med. Chem.28(7)849-857.
Miranker and Karplus, 1991, “Functionality maps of binding sites: a multiple copy simultaneous search method”,Proteins11(1)29-34.
Goodsell and Olsen, 1990, “Automated docking of substrates to proteins by simulated annealing”,Proteins8(3):195-202.
Kuntz et al., 1982, “A geometric approach to macromolecule-ligand interactions”,J. Mol. Biol.161(2):269-288.
Van Drie et al., 1989, “ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures”,J. Comp-Aided Mol. Des.3(3):225-251.
Davie and Lawrence, 1992, “CLIX: a search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure”,Proteins12(1):31-41.
Rotstein and Murcko, 1993, “GroupBuild: a fragment-based method for de novo drug design”,J. Med. Chem.36(12):1700-1710.
Moon and Howe, 1991, “Computer design of bioactive molecules: a method for receptor-based de novo ligand design”,Proteins11(4):314-328.
Bohm, 1992, “The computer program LUDI: a new method for the de novo design of enzyme inhibitors”,J. Comp. Aid. Molec. Design6(1):61-78.
Jorgenson and Duffy, 2000, “Prediction of drug solubility from Monte Carlo simulations”,Bioorg. Med. Chem. Lett.10(11):1155-1158.
Nishibata and Itai, 1991, “Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation.”,Tetrahedron47:8985.
Cohen et al., 1990, “Molecular modeling software and methods for medicinal chemistry”,J. Med Chem.33(3):883-394.
Navia and Murcko, 1992, “Use of structural information in drug design”,Current Opinions in Structural Biology 2:202-210.
Jorgenson WL, Encylopedia of Computational Chemistry (P. V. R. Schleyer, ed.) Wiley & Sonstra., Athens, U.S.A. 5:3281-3285, Goodman Gilman, Rall, Nies, & Taylor, eds.), Pergaman Press.
Lam et al., 1994, “Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors”,Science263(5145):380-4.
Wlodawer et al., 1993, “Structure-based inhibitors of HIV-1 protease”,Ann. Rev. Biochem.62:543-585.
Appelt, 1993, “Crystal structures of HIV-1 prtotease inhibitor complexes”,Perspectives in Drug Discovery and Design 1:23-48.
Erickson, 1993, “Design and structure of symmetry-based inhibitors of HIV-1 protease”,Perspectives in Drug Discovery and Design 1:109-128.
Mayer et al., 1987, “A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies”,J. Comp. Aided Molec. Design1(1):3-16.
Dunbrack et al., 1997, “Meeting review: the Second meeting on the Critical Asssesment of Techniques for Protein Structure Prediction (CASP2), Asilomar, California, Dec. 13-16, 1996”,Folding&Design2(2):R27-42.
Bugg et al., 1993, “Drugs by design”,Scientific AmericanDec:92-98.
West et al., 1995, “Targetign HIV-1 protease: a test of drug-design methodologies”,TIPS16:67-74.
Sidman et al., 1983, “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid”,Biopolymers22(1):547-556.
Langer et al., 1981, “Biocompatibility of polymeric delivery systems for macromolocules”,J. Biomed. Mater. Res.15:167-277.
Langer, 1982, “Controlled release of macromolecules”,Chem. Tech. 12:98-105.
Eppstein et al., 1985, “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor”,Proc. Natl. Acad. Sci. USA82(11):3688-3692.
Esnault et al., 2002, “GM-CSF regulation in eosinophils”,Arch. Immunol. Ther. Exp(Warsz). 50(2):121-130.
Esnault and Malter 2001, “Granulocyte macrophage-colony-stimulating factor mRNA is stabilized in airway eosinophils and peripheral blood eosinophils activated by TNF-alpha plus fibronectin”,J. Immunol.166(7):4658-4663.
Schreiber and Crabtree, 1992, “The mechanism of action of cyclosporin A and FK506”,Immunol. Today13(4)136-142.
Khan et al., 2000, “Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin”,Am. J. Respir. Crit. Care Med.162(4 Pt 1):1377-1382.
Kita, H. et al. 1991, “Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils”,J Exp Med.174(3):745-748.
Hennig, L. et al. 1998, “Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone”,Biochemistry37(17):5953-5960.
Esnault, S. & Malter, J. S, 2003, “Hyaluronic acid or TNF-alpha plus fibronectin triggers granulocyte macrophage-colony-stimulating factor mRNA stabilzation in eosinophils yet engages differential intracellular pathways and mRNA binding proteins”,J. Immunol.171(12)6780-6787.
Lu et

Affiliated with

Also associated with

Rating

Blockade of Pin1 prevents cytokine production by activated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Blockade of Pin1 prevents cytokine production by activated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blockade of Pin1 prevents cytokine production by activated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4015443